Literature DB >> 18384541

Presence of residual basal cell carcinoma in re-excised specimens is more probable when deep and lateral margins were positive.

J D Fernandes1, M C de Lorenzo Messina, E R de Almeida Pimentel, L G M Castro.   

Abstract

In order to quantify presence of residual BCC in patients with histologic positive margins after the first excision and to correlate the presence of residual tumor in re-excised lesions with the location of the positive margin on the first excision, a retrospective evaluation of 2053 surgically treated BCC was performed. Only 38.3% of the re-excised lesions showed residual tumor. In the group of re-excised lesions where residual BCC was found, 13% had lateral positive margin in the first excision, 39% had deep positive margin and 48% had both lateral and deep positive margins. In the group of re-excised lesions where no residual BCC was found, 49% of the primary excised lesions had lateral positive margin, 32% had deep positive margin and 19% had both deep and lateral positive margins. The association between residual tumor and positive margins was statistically significant (p = 0.01). Our findings confirm that presence of residual tumour is more likely when both lateral and deep margins are compromised.

Entities:  

Mesh:

Year:  2008        PMID: 18384541     DOI: 10.1111/j.1468-3083.2007.02571.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  2 in total

1.  Expression of matrix metalloproteinase-1, -9, -13, and tissue inhibitor of metalloproteinases-1 in basal cell carcinomas of the eyelid.

Authors:  Zornitsa I Zlatarova; Ekaterina B Softova; Klara G Dokova; Elisabeth M Messmer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-09-01       Impact factor: 3.117

2.  Evaluation of surgical margins according to the histological type of basal cell carcinoma.

Authors:  Charles Antonio Pires de Godoy; Alice Lima de Oliveira Neta; Sofia Silveira de Souza Leão; Raul Lima Dantas; Valeska Oliveira Fonseca Carvalho; Samuel Freire da Silva
Journal:  An Bras Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.